MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
COR stock logo

COR

Cencora, Inc.

$279.57
5.49
 (2%)
Exchange:  NYSE
Market Cap:  54.393B
Shares Outstanding:  40M
Delayed data
Calculate COR Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Distribution
   
CEO:  Robert Mauch
Full Time Employees:  47000
Address: 
1 West First Avenue
Conshohocken
PA
19428-1800
US
Website:  https://www.cencora.com
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/02/04 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue262,173,411293,958,599321,332,819
Gross Profit7,756,4978,701,23810,141,521
EBITDA3,408,8793,364,3313,736,333
Operating Income2,446,5133,040,1323,647,679
Net Income1,745,2931,509,1201,554,169

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets62,558,74667,101,66776,590,112
Total Liabilities61,892,45966,314,92574,843,027
Total Stockholders Equity522,003645,9381,747,085
Total Debt4,787,4574,388,0767,660,773
Cash and Cash Equivalents2,592,0513,132,6484,356,138

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow3,911,3343,484,6853,875,120
Capital Expenditure-458,359-487,173-667,981
Free Cash Flow3,452,9752,997,5123,207,139
Net Income1,732,5761,519,2731,567,814
Net Change in Cash-840,650544,9911,096,669

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)378,133,465.769Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)392,725,030.569Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)384,624,800Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)4,743,256.075Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)4,926,290.730Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)4,824,682.511Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)5,926,497.952Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)6,225,339.353Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)6,059,442.591Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)7,323,770.062Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)7,606,382.618Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)7,449,495.615Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)31.040Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)31.890Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)30.360Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)8Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
293.959B  ?P/S
 (TTM)
: 
0.16
?Net Income
 (TTM)
: 
1.509B  ?P/E
 (TTM)
: 
20.99
?Enterprise Value
 (TTM)
: 
63.661B  ?EV/FCF
 (TTM)
: 
40.86
?Dividend Yield
 (TTM)
: 
0.01  ?Payout Ratio
 (TTM)
: 
0.18
?ROE
 (TTM)
: 
1.16  ?ROIC
 (TTM)
: 
0.12
?Net Debt
 (TTM)
: 
4.821B  ?Debt/Equity
 (TTM)
: 
3.65
?P/B
 (TTM)
: 
15.75  ?Current Ratio
 (TTM)
: 
0.95

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
15.73Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates COR intrinsic value between $184.10 – $220.22 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about COR valuation

Is Cencora, Inc. (COR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Cencora, Inc. (COR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is COR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether COR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is COR’s P/E ratio?

You can see COR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for COR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is COR a good long-term investment?

Whether COR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

COR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2
MARKETSnap

Trading Metrics:

Open: 272.2   Previous Close: 274.08
Day Low: 270.64   Day High: 279.88
Year Low: 244.82   Year High: 377.54
Price Avg 50: 291.98   Price Avg 200: 325.37
Volume: 1.224M   Average Volume: 1.774M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
05-06-2026 12:36
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
14-05-2026 22:25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
Cencora revises forecast for 2026, approves $2 billion share buyback
21-05-2026 17:13
Cencora revises forecast for 2026, approves $2 billion share buyback
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
21-05-2026 16:30
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR
15-05-2026 19:20
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
13-05-2026 13:20
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read